Invention Grant
US07687523B2 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
有权
3-杂芳基-3,9-二氮杂双环[3.3.1]壬烷衍生物作为烟碱乙酰胆碱受体激动剂
- Patent Title: 3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists
- Patent Title (中): 3-杂芳基-3,9-二氮杂双环[3.3.1]壬烷衍生物作为烟碱乙酰胆碱受体激动剂
-
Application No.: US12087004Application Date: 2007-02-09
-
Publication No.: US07687523B2Publication Date: 2010-03-30
- Inventor: Dan Peters , Daniel B. Timmermann , Gunnar M. Olsen , Elsebet Østergaard Nielsen , Jeppe Kejser Christensen
- Applicant: Dan Peters , Daniel B. Timmermann , Gunnar M. Olsen , Elsebet Østergaard Nielsen , Jeppe Kejser Christensen
- Applicant Address: DK Ballerup
- Assignee: Neurosearch A/S
- Current Assignee: Neurosearch A/S
- Current Assignee Address: DK Ballerup
- Agency: Birch, Stewart, Kolasch & Birch, LLP
- Priority: DK200600190 20060210
- International Application: PCT/EP2007/051272 WO 20070209
- International Announcement: WO2007/090888 WO 20070816
- Main IPC: A61K31/44
- IPC: A61K31/44
![3-heteroaryl-3,9-diazabicyclo[3.3.1]nonane derivatives as nicotinic acetylcholine receptor agonists](/abs-image/US/2010/03/30/US07687523B2/abs.jpg.150x150.jpg)
Abstract:
Compounds of the class 3,9-diaza-bicyclo [3.3.1]nonane derivatives. The compounds correspond to structural Formula (I): wherein Ra is hydrogen or optionally substituted alkyl and Rb is a monocyclic heteroaryl group. The compounds are useful in the treatment, prevention, or alleviation of diseases or disorders or conditions that are responsive to modulation of nicotinic acetylcholine receptors, including cognitive disorders, Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, Bipolar Disorder, obsessive compulsive disorders (OCD), narcolepsy, senile dementia, autism, Parkinson'disease, Amyotrophic Lateral Sclerosis, epilepsy, and diabetic neuropathy.
Public/Granted literature
- US20090005388A1 3-Heteroaryl-3,9-Diazabicyclo[3.3.1]Nonane Derivatives as Nicotinic Acetylcholine Receptor Agonists Public/Granted day:2009-01-01
Information query